A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine

[1]  M. Plummer,et al.  Worldwide burden of cancer attributable to HPV by site, country and HPV type , 2017, International journal of cancer.

[2]  Yan Wang,et al.  PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer , 2017, Clinical Cancer Research.

[3]  P. Delvenne,et al.  Deciphering the Multifactorial Susceptibility of Mucosal Junction Cells to HPV Infection and Related Carcinogenesis , 2017, Viruses.

[4]  Keith Lai,et al.  Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma , 2017, The Journal of pathology.

[5]  B. Falk,et al.  A Semipersistent Plant Virus Differentially Manipulates Feeding Behaviors of Different Sexes and Biotypes of Its Whitefly Vector , 2017, Viruses.

[6]  V. Dutta,et al.  Mucinous adenocarcinoma of perianal region: an uncommon disease treated with neo-adjuvant chemo-radiation. , 2016, Translational gastroenterology and hepatology.

[7]  Y. Akagi,et al.  mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma , 2016, Case Reports in Oncology.

[8]  D. Chan,et al.  Case report of an anal adenocarcinoma arising from a perineal lump , 2016, Annals of medicine and surgery.

[9]  D. van Baarle,et al.  Differences in T-cell infiltrates and survival between HPV+ and HPV- oropharyngeal squamous cell carcinoma , 2016, Future science OA.

[10]  P. Delvenne,et al.  Carcinogenic HPV infection in the cervical squamo‐columnar junction , 2015, The Journal of pathology.

[11]  J. Beijnen,et al.  HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53 , 2015, British Journal of Cancer.

[12]  F. McKeon,et al.  Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPV-related cancer risk , 2015, Modern Pathology.

[13]  J. Foidart,et al.  Altered α‐defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour‐permissive microenvironment , 2014, The Journal of pathology.

[14]  E. Pirog,et al.  HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases , 2014, Modern Pathology.

[15]  E. Høgdall,et al.  Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Coppedè,et al.  Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens , 2014, Epigenetics.

[17]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[18]  D. Sebag‐Montefiore,et al.  Adenocarcinoma of the anal canal – a systematic review , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[19]  R. Sun,et al.  P16INK4A as a surrogate biomarker for human papillomavirus‐associated oropharyngeal carcinoma: Consideration of some aspects , 2013, Cancer science.

[20]  Nikhil Wagle,et al.  Oncogenic mutations in cervical cancer , 2013, Cancer.

[21]  M. Ducreux,et al.  Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. , 2013, Cancer treatment reviews.

[22]  F. McKeon,et al.  Cervical Squamocolumnar Junction–specific Markers Define Distinct, Clinically Relevant Subsets of Low-grade Squamous Intraepithelial Lesions , 2013, The American journal of surgical pathology.

[23]  J. Bosset,et al.  Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. , 2013, Human pathology.

[24]  J. Ledermann,et al.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. , 2013, The Lancet. Oncology.

[25]  M. Márquez,et al.  Adenocarcinoma of the anal canal. Narrative review , 2013 .

[26]  M. Márquez,et al.  Adenocarcinoma del canal anal. Revisión de conjunto , 2013 .

[27]  N. Merrett,et al.  Transcriptionally Active Human Papillomavirus Is Strongly Associated With Barrett's Dysplasia and Esophageal Adenocarcinoma , 2013, The American Journal of Gastroenterology.

[28]  Levi Waldron,et al.  Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum , 2012, Gut.

[29]  M. Poljak,et al.  Comparison of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for the detection of human papillomaviruses in formalin-fixed, paraffin-embedded cervical cancer specimens. , 2011, Journal of virological methods.

[30]  E. Dozois,et al.  Neoplasms of Anal Canal and Perianal Skin , 2011, Clinics in colon and rectal surgery.

[31]  V. Karantza,et al.  Keratins in health and cancer: more than mere epithelial cell markers , 2011, Oncogene.

[32]  J. B. Carpenter,et al.  Immunophenotypic characteristics of anal gland carcinoma. , 2009, Archives of pathology & laboratory medicine.

[33]  R. Gonzalez,et al.  A Twenty-Year Experience with Adenocarcinoma of the Anal Canal , 2009, Diseases of the colon and rectum.

[34]  P. Delvenne,et al.  Epithelial metaplasia: adult stem cell reprogramming and (pre)neoplastic transformation mediated by inflammation? , 2009, Trends in molecular medicine.

[35]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[36]  P. Delvenne,et al.  Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. , 2008, The American journal of pathology.

[37]  K. Cymes,et al.  Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6. , 2007, Archives of pathology & laboratory medicine.

[38]  J. Berlin,et al.  Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. , 2007, Clinical colorectal cancer.

[39]  L. Akslen,et al.  Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients , 2006, International journal of cancer.

[40]  E. Friedman,et al.  Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Hoheisel,et al.  Array-based analysis of genomic DNA methylation patterns of the tumour suppressor gene p16INK4A promoter in colon carcinoma cell lines , 2005, Nucleic acids research.

[42]  D. Kennedy.  Breakthrough of the Year , 2004, Science.

[43]  Richard L Schilsky,et al.  Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[44]  A. Duval,et al.  Quasimonomorphic Mononucleotide Repeats for High-Level Microsatellite Instability Analysis , 2004, Disease markers.

[45]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[46]  R. Mirimanoff,et al.  Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. , 2003, International journal of radiation oncology, biology, physics.

[47]  E. Lin,et al.  Chemoradiation for adenocarcinoma of the anus. , 2003, International journal of radiation oncology, biology, physics.

[48]  A. Hongo,et al.  Rapid and Sensitive Detection of Physical Status of Human Papillomavirus Type 16 DNA by Quantitative Real-Time PCR , 2002, Journal of Clinical Microbiology.

[49]  N. Petrelli,et al.  Prognosis and recurrence patterns of anal adenocarcinoma. , 1995, American journal of surgery.

[50]  M. Abel,et al.  Adenocarcinoma of the anal glands , 1993, Diseases of the colon and rectum.

[51]  L. Gissmann,et al.  A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[52]  T. Sakamoto,et al.  Adenocarcinoma arising from an anal gland-Report of a case. , 2014, International journal of surgery case reports.

[53]  H. Nemoto,et al.  Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer. , 2009, Anticancer research.

[54]  V. Knysh,et al.  [Adenocarcinoma of the anal canal]. , 1986, Voprosy onkologii.